Showing results (111-120 of 279) with videos related to

Sort By:
Pageof 28
Blood Advances|July 28, 2019
A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosisJason Gotlib, John H Baird, Tracy I George, et al.
British Journal of Haematology|January 21, 2010
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasmsClaire Hidalgo-Curtis, Jane F Apperley, Allistair Stark, et al.
Archives of Pathology & Laboratory Medicine|April 19, 2022
Most Frequently Cited Accreditation Inspection Deficiencies for Clinical Molecular Oncology Testing Laboratories and Opportunities for ImprovementNikoletta Sidiropoulos, Sarah K Daley, Marian Briggs, et al.
Archives of Pathology & Laboratory Medicine|September 5, 2019
Comparative Performance of High-Risk Human Papillomavirus RNA and DNA In Situ Hybridization on College of American Pathologists Proficiency TestsElaine S Keung, Rhona J Souers, Julia A Bridge, et al.
Archives of Pathology & Laboratory Medicine|June 10, 2022
Clinical Testing for Tumor Cell-Free DNA: College of American Pathologists Proficiency Programs Reveal Practice TrendsKelly A Devereaux, Rhona J Souers, Jason D Merker, et al.
Blood Neoplasia|December 22, 2025
Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinibEmily C Liang, Cecelia Perkins, Rong Lu, et al.
Blood Advances|September 8, 2021
A novel activating JAK1 mutation in chronic eosinophilic leukemiaWilliam Shomali, Alisa Damnernsawad, Talent Theparee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2016
A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphomaMichael G Ozawa, Aparna Bhaduri, Karen M Chisholm, et al.
Leukemia Research|May 18, 2021
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)Fiona Taylor, Xiaoran Li, Christine Yip, et al.
Leukemia & Lymphoma|June 17, 2020
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Asiri Ediriwickrema, Ritika Dutta, et al.
Pageof 28